Implications of the FDA approval of PCSK9 inhibitors and FOURIER results for contemporary cardiovascular practice: An NCDR Research to Practice (R2P) project

Am Heart J. 2018 Jan:195:151-152. doi: 10.1016/j.ahj.2017.09.004. Epub 2017 Sep 9.
No abstract available

Publication types

  • Letter
  • Research Support, N.I.H., Extramural
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Antibodies, Monoclonal* / economics
  • Antibodies, Monoclonal* / pharmacology
  • Antibodies, Monoclonal, Humanized
  • Anticholesteremic Agents / economics
  • Anticholesteremic Agents / pharmacology
  • Arteriosclerosis* / blood
  • Arteriosclerosis* / drug therapy
  • Cholesterol, LDL / blood
  • Cost-Benefit Analysis
  • Drug Approval
  • Eligibility Determination / methods
  • Female
  • Humans
  • Male
  • Medication Therapy Management
  • Middle Aged
  • PCSK9 Inhibitors*
  • Registries / statistics & numerical data
  • Treatment Outcome
  • United States

Substances

  • Antibodies, Monoclonal
  • Antibodies, Monoclonal, Humanized
  • Anticholesteremic Agents
  • Cholesterol, LDL
  • PCSK9 Inhibitors
  • PCSK9 protein, human
  • evolocumab